Alnylam Pharmaceuticals Inc

Overview

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops and commercializes therapeutics based on RNAi interference. The company’s marketed RNAi therapeutics include, Onpattro, is used in treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for treatment of acute hepatic porphyria, Oxlumo developed for treatment of primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late-stage product candidates include vutrisiran for ATTR amyloidosis, inclisiran for hypercholesterolemia, fitusiran for hemophilia and rare bleeding disorders, and lumasiran for severe PH1. The company operates subsidiaries in the US, Austria, Belgium, Bermuda, Canada, France, Germany, Italy, Japan, Taiwan, Portugal, Spain, Sweden, the Netherlands, Switzerland, Czech Republic, and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.
Key Stats
Address
675 W Kendall St, CAMBRIDGE, Massachusetts
Headquarters

United States of America

Contact

1 617 5518200

Website
www.alnylam.com
No of Employees

1,453

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

ALNY [NASD]

Revenue (2020)

$493 m

124.4% (2020 vs 2019)
Net Income (2020)

$-858 m

3.2% (2020 vs 2019)
Net Profit Margin

-174 %

56.8% (2020 vs 2019)
Market Cap *

$22,143 m

EPS *

$-7.5

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Alnylam Pharmaceuticals IncF. Hoffmann-La Roche LtdPfizer IncArrowhead Pharmaceuticals Inc
Key Information
Headquarters United States of America Switzerland United States of America United States of America
Headquarter City CAMBRIDGE BASEL NEW YORK PASADENA
Headquarter State/Province Massachusetts - New York California
No. of Employees 1,453 101,465 78,500 98
Entity Type Public Public Public Public

Products & Services

Alnylam researches and develops innovative medicines based on the biology known as RNA interference. Key products and pipeline offered by the company include:

Products
  • Marketed:
  • Onpattro - RNAi therapeutic for treatment of hATTR amyloidosis
  • Givlaari - Acute Hepatic Porphyria
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • Onpattro
  • Givlaari
  • Oxlumo
  • Rutrum Elit
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Tolga Tanguler Chief Commercial Officer Senior Management 2021 - Mr. Tolga Tanguler serves as Chief Commercial Officer at the company since January 2021. Prior to this, he served as...
Yvonne L. Greenstreet Chief Operating Officer; President Senior Management 2020 58 Ms. Yvonne Greenstreet has been the Chief Operating Officer and the President of the company since October 2020. Prior to...
Laurie B. Keating Secretary; Chief Legal Officer; Executive Vice President Senior Management 2019 67 Ms. Laurie B. Keating is the Executive Vice President, Chief Legal Officer and Secretary of the company since 2019. Prior...
Jeff Poulton Executive Vice President; Chief Financial Officer Senior Management 2019 53 Mr. Jeff Poulton has been the Chief Financial Officer and the Executive Vice President of the company since 2019. Prior...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Contracts/Agreements In March, the company and Gen, a GMP-certified pharmaceutical company entered into an agreement to…
2020 Financing Agreements In April, the company raised US$2 billion from Blackstone to support its advancement of innovative…
2020 Contracts/Agreements In March, the company extended its existing partnership with Vir Biotechnology to advance RNAi therapeutics…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Alnylam Securities Corp

Address

300 3rd Street no.3, Cambridge
United States of America

Telephone

1 617 5518200

Alnylam Europe AG

Address

Fritz-Hornschuch-Str. 9, Kulmbach
Germany

Telephone

49 9221 827620

Alnylam UK Ltd

Address

Braywick Gate, Braywick Rd, Maidenhead
United Kingdom

Telephone

44 1255 444400

Alnylam Germany GmbH

Address

Maximilian Strasse 35a, Munich
Germany

Telephone

49 89 24218118

Alnylam Italy Srl

Address

Via LePetit 8/10, Milan
Italy

Telephone

39 289 732291

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
29 Jul 2021 Alnylam Pharma Enters into Licensing Agreement with PeptiDream Licensing Agreement Alnylam Pharmaceuticals Inc PeptiDream Inc
03 Dec 2020 Orsini Specialty Enters into Distribution Agreement with Alnylam Pharma Partnership Orsini Healthcare; Alnylam Pharmaceuticals Inc
23 Nov 2020 Alnylam Pharmaceuticals Enters Manufacturing Agreement with Vetter Pharma-Fertigung for Oxlumo Contract Service Agreement Alnylam Pharmaceuticals Inc Vetter Pharma-Fertigung GmbH & Co KG
18 Sep 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
13 Apr 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
13 Apr 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

119

Active Jobs

55

Posted

42

Closed

Job Trends

Latest Jobs

Job title Company Country
Scientist Alnylam Pharmaceuticals Inc United States
Medical Science Liaison, Brazil Alnylam Pharmaceuticals Inc Brazil
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar